PDGF B Human

PDGF was first discovered in the late 1980s during animal studies conducted by Lynch and co-workers . It is present in serum but absent from plasma, indicating its release during platelet activation. PDGF-BB, one of the three subforms of PDGF (PDGF-AA, PDGF-BB, PDGF-AB), is a disulfide-linked dimer consisting of two B chains .

PDGF-BB is expressed by various cell types, including vascular endothelium, megakaryocytes, and Leydig cells . It targets pericytes, fibroblasts, monocytes, and other cell types, inducing fibroblast growth and migration . Additionally, PDGF-BB acts as a chemoattractant for monocytes and granulocytes .

Recombinant human PDGF-BB (rhPDGF-BB) is produced using recombinant DNA technology, typically in E. coli . This recombinant form is used extensively in research and therapeutic applications due to its high purity and bioactivity . The bioactivity of rhPDGF-BB is determined through cell proliferation assays, with an effective dose (ED50) ranging between 4.0 - 15 ng/ml .

PDGF-BB has several applications in medical research and therapy. It is particularly important in the field of tissue engineering and regenerative medicine due to its ability to stimulate cell growth and tissue repair . PDGF-BB is also used in studies related to cancer, as it plays a role in tumor growth and metastasis .

Recombinant PDGF-BB is typically lyophilized and stored at -20°C to maintain its stability . Once reconstituted, it remains stable at 4°C for up to two months and at -20°C for up to six months . It is crucial to avoid repeated freeze-thaw cycles to preserve its bioactivity .